Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK May Launch Boostrix Vaccine Ahead Of June CDC Recommendation

This article was originally published in The Pink Sheet Daily

Executive Summary

The tetanus, diphtheria and pertussis vaccine clears FDA for patients ages 10 through 18. The vaccine approval follows the advisory committee's 13-0 unanimous recommendation in favor of use in that population, as well as its recommendation for a postmarketing trial.

You may also be interested in...



Boostrix And Adacel Get Universal Recommendation For 11-12 Year-Olds

CDC’s Advisory Committee on Immunization Practices also recommends catch-up Tdap vaccination for adolescents who have already received a Td booster. ACIP further recommends concomitant administration of Tdap with Sanofi-Aventis’ meningococcal conjugate vaccine Menactra.

Boostrix And Adacel Get Universal Recommendation For 11-12 Year-Olds

CDC’s Advisory Committee on Immunization Practices also recommends catch-up Tdap vaccination for adolescents who have already received a Td booster. ACIP further recommends concomitant administration of Tdap with Sanofi-Aventis’ meningococcal conjugate vaccine Menactra.

Sanofi-Aventis' Adacel Launch Plans Await CDC Recommendations

FDA clears the tetanus, diphtheria, pertussis booster vaccine for individuals ages 11-64. Phase IV commitments include a concomitant use study with Sanofi's meningococcal vaccine Menactra.

Related Content

Topics

UsernamePublicRestriction

Register

PS062299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel